Finance

Lists
Why is 6919 up 9.68%?
Dive Deeper
6919:TPE
Caliway Biopharmaceuticals Co Ltd
NT$74.80
+9.68%
(+6.60) 1D
Nov 17, 1:30:31 PM GMT+8  ·   TWD
All symbols
SymbolPriceChange% Change
Generating top insights for 6919...
Open
NT$67.90
High
NT$75.00
Low
NT$66.40
Mkt. cap
116.48B
Avg. vol.
5.41M
Volume
12.75M
52-wk high
NT$188.00
52-wk low
NT$59.90
EPS
-NT$0.39
Open
NT$67.90
High
NT$75.00
Low
NT$66.40
Mkt. cap
116.48B
Avg. vol.
5.41M
Volume
12.75M
52-wk high
NT$188.00
52-wk low
NT$59.90
EPS
-NT$0.39
News stories
From web sources and news partners
About Caliway Biopharmaceuticals Co Ltd
CEO-
Employees-
Founded2012
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Next call in 5 days
Mon, Nov 23, 5:00 AM
Fiscal period
Q3 2026
- / -NT$0.20
Revenue / Est. (TWD)
- / 8.00M
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in TWD
Loading Previous Earnings...
Revenue
Net income
All values in TWD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
12.41M
2.00K
3.57M
-
Cost of goods sold
3.40M
1.00K
1.24M
-
Cost of revenue
3.40M
1.00K
1.24M
-
Research and development expenses
112.62M
212.41M
210.66M
434.44M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
17.06M
33.42M
54.75M
51.64M
Operating expense
129.69M
245.83M
265.41M
486.08M
Total operating expenses
133.09M
245.83M
266.65M
486.08M
Operating income
-120.68M
-245.83M
-263.08M
-486.08M
Other non operating income
9.00K
-4.00K
-2.00K
40.28M
EBT including unusual items
80.19M
-107.75M
-222.52M
-361.24M
EBT excluding unusual items
80.19M
-107.75M
-222.52M
-361.24M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
80.19M
-107.75M
-222.52M
-361.24M
Net profit margin
646.17%
-5,387,700.00%
-6,239.93%
-
Earnings per share
0.05
-0.07
-0.14
-
Interest and investment income
85.42M
78.51M
82.27M
85.52M
Interest expense
-22.00K
-11.00K
-329.00K
-953.00K
Net interest expenses
85.40M
78.50M
81.94M
84.56M
Depreciation and amortization charges
-
-
-
-
EBITDA
-114.79M
-239.81M
-258.15M
-476.10M
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google apps